

## 1 Trade name

Entresto® film-coated tablets 50 mg.

Entresto® film-coated tablets 100 mg.

Entresto® film-coated tablets 200 mg.

## 2 Description and Composition

### Pharmaceutical form

Film-coated tablets.

50 mg: Violet white ovaloid biconvex film-coated tablet with beveled edges, unscored, debossed with “NVR” on one side and “LZ” on the other side.


100 mg: Pale yellow ovaloid biconvex film-coated tablet with beveled edges, unscored, debossed with “NVR” on one side and “L1” on the other side.

200 mg: Light pink ovaloid biconvex film-coated tablet with beveled edges, unscored, debossed with “NVR” on one side and “L11” on the other side.

### Active substances

Sacubitril/Valsartan Sodium salt complex equivalent to sacubitril/valsartan anhydrous acid.

Entresto® contains a salt complex of the anionic forms of sacubitril and valsartan, sodium cations, and water molecules in the molar ratio of 1:1:3:2.5 respectively. The empirical formula of the complex (hemipentahydrate) is  $C_{48}H_{55}N_6O_8Na_3 \cdot 2.5 H_2O$ . Its molecular mass is 957.99 and its schematic structural formula is



Following oral administration, the complex dissociates into sacubitril (which is further metabolized to sacubitrilat) and valsartan.

### **Single dose strengths**

Entresto film coated tablets contains 50 mg (24.3mg sacubitril/25.7mg valsartan)\*.

Entresto film coated tablets contains 100 mg (48.6mg sacubitril/51.4mg valsartan)\*.

Entresto film coated tablets contains 200 mg (97.2mg sacubitril/102.8mg valsartan)\*.

\*Information may differ in some countries.

### **Excipients**

microcrystalline cellulose, low-substituted hydroxypropylcellulose, crospovidone, magnesium stearate (vegetable origin), talc and colloidal silicon dioxide

Excipients of film coating:

hypromellose, titanium dioxide (E 171), Macrogol 4000, talc, iron oxide red (E 172)

For 50 and 200 mg: iron oxide black (E 172).

For 100mg: iron oxide yellow (E 172).

## **3 Indications**

### **Heart Failure**

Entresto is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction.

Entresto is usually administered in conjunction with other heart failure therapies, in place of an ACE inhibitor or other ARB.

### **Hypertension**

Entresto is indicated for the treatment of essential hypertension.

## **4 Dosage regimen and administration**

### **Dosage regimen**

#### **Heart Failure**

The target dose of Entresto is 200 mg twice daily.

The recommended starting dose of Entresto is 100 mg twice daily. A starting dose of 50 mg twice daily is recommended for patients not currently taking an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin II receptor blocker (ARB), and should be considered for patients previously taking low doses of these agents (see section 12 Clinical studies).

The dose of Entresto should be doubled every 2-4 weeks to the target dose of 200 mg twice daily, as tolerated by the patient.

Due to the potential risk of angioedema when used concomitantly with an ACE inhibitor, Entresto must not be started until 36 hours after discontinuing ACE inhibitor therapy (see section 5 Contraindications).

Entresto should not be co-administered with an ARB due to the angiotensin II receptor blocking activity of Entresto (see sections 6 Warnings and precautions, and 8 Interactions).

If patients experience tolerability issues (symptomatic hypotension, hyperkalemia, renal dysfunction), consideration should be given to adjustment of concomitant medications, or to temporary down-titration of Entresto.

### **Essential hypertension**

The recommended starting dose of Entresto is 200 mg once daily. In patients whose blood pressure could not be adequately controlled with Entresto 200 mg once daily, the dose can be increased to 400 mg once daily. In hypertensive patients with heart failure, the heart failure dosing is recommended.

Entresto may be used alone or in combination with other antihypertensive agents except angiotensin-converting enzyme (ACE) inhibitors (see section 5 Contraindications) and angiotensin II receptor blockers (ARBs) (see section 6 Warnings and precautions)

### **Special populations**

#### **Renal impairment**

A starting dose of 50 mg twice daily is recommended in heart failure patients with severe renal impairment (eGFR <30 mL/min/1.73 m<sup>2</sup>). Caution is recommended when using Entresto in these patients due to limited data (see section 11 Clinical pharmacology).

Safety and efficacy of Entresto in patients with essential hypertension and with severe renal impairment (eGFR <30 mL/min/1.73 m<sup>2</sup>) have not been established (see section 11 Clinical pharmacology).

No dose adjustment is required in patients with mild (eGFR 60-90 mL/min/1.73 m<sup>2</sup>) to moderate (eGFR 30-60 mL/min/1.73 m<sup>2</sup>) renal impairment.

#### **Hepatic impairment**

A starting dose of 50 mg twice daily is recommended for heart failure patients with moderate hepatic impairment (Child-Pugh B classification).

A starting dose of 100 mg once daily is recommended for essential hypertensive patients with moderate hepatic impairment (Child-Pugh B classification).

No dose adjustment is required when administering Entresto to patients with mild hepatic impairment (Child-Pugh A classification).

No studies have been conducted in patients with severe hepatic impairment (Child-Pugh C classification). Therefore, use of Entresto in these patients is not recommended (see section 11 Clinical pharmacology).

#### **Pediatric patients (below 18 years of age)**

The safety and efficacy of Entresto in pediatric patients aged below 18 years has not been established.

### **Geriatric patients (65 years of age and above)**

No dosage adjustment is required in patients 65 years of age and above.

### **Method of administration**

For oral use. Entresto may be administered with or without food (see section 11 Clinical pharmacology).

## **5 Contraindications**

- Hypersensitivity to the active substance, sacubitril, valsartan, or to any of the excipients.
- Concomitant use with ACE inhibitors (see sections 6 Warnings and precautions, 4 Dosage regimen and administration, and 8 Interactions). Entresto must not be administered until 36 hours after discontinuing ACE inhibitor therapy.
- Known history of angioedema related to previous ACE inhibitor or ARB therapy.
- Hereditary angioedema.
- Concomitant use with aliskiren-containing products in patients with diabetes mellitus or renal impairment (eGFR < 60ml/min/1.73 m<sup>2</sup>) (see sections 6 Warnings and precautions and 8 Interactions).
- Pregnancy (see section 9 Pregnancy, lactation, females and males of reproductive potential).
- Severe renal impairment with eGFR <10 ml/min/1.73 m<sup>2</sup> and patients undergoing dialysis due to lack of data.

## **6 Warnings and precautions**

### **Dual blockade of the Renin-Angiotensin-Aldosterone System (RAAS)**

- Entresto must not be administered with an ACE inhibitor due to the risk of angioedema. Entresto must not be initiated until 36 hours after taking the last dose of ACE inhibitor therapy. If treatment with Entresto is stopped, ACE inhibitor therapy must not be initiated until 36 hours after the last dose of Entresto (see sections 5 Contraindications, 4 Dosage regimen and administration, and 8 Interactions).
- Caution is required while co-administering Entresto with direct renin inhibitors such as aliskiren (see sections 5 contraindications and 8 Interactions). Entresto must not be administered with aliskiren-containing products in patients with diabetes mellitus or renal impairment (eGFR < 60ml/min/1.73m<sup>2</sup>) (see section 5 contraindications).
- Entresto should not be co-administered with an ARB due to the angiotensin II receptor blocking activity of Entresto (see sections 4 Dosage regimen and administration, and 8 Interactions).

## **Hypotension**

Cases of symptomatic hypotension have been reported in patients treated with Entresto during clinical trials. If hypotension occurs, dose adjustment of diuretics, concomitant antihypertensive drugs, and treatment of other causes of hypotension (e.g. hypovolemia) should be considered. If hypotension persists despite such measures, the dosage of Entresto should be reduced or the product should be temporarily discontinued (see section 4 Dosage regimen and administration).

Permanent discontinuation of therapy is usually not required. Symptomatic hypotension is more likely to occur if the patient has been volume-depleted, e.g., by diuretic therapy, dietary salt restriction, diarrhea or vomiting. Sodium and/or volume depletion should be corrected before starting treatment with Entresto.

## **Renal impairment**

As for any drug that acts on the renin-angiotensin-aldosterone system, use of Entresto may be associated with decreased renal function. In PARADIGM-HF, associated treatment discontinuation was observed less frequently in patients receiving Entresto (0.65%) compared to enalapril (1.28%).

In patients whose renal function depends upon the activity of the renin-angiotensin-aldosterone system (e.g., patients with severe congestive heart failure), treatment with ACE inhibitors and angiotensin receptor antagonists has been associated with oliguria, progressive azotemia and, rarely, acute renal failure and death. Closely monitor serum creatinine, and down-titrate or interrupt Entresto in patients who develop a clinically significant decrease in renal function. Caution should be exercised when administering Entresto in patients with severe renal impairment (see sections 4 Dosage regimen and administration, 5 Contraindications and 11 Clinical pharmacology).

## **Hyperkalemia**

As for any drug that acts on the renin-angiotensin-aldosterone system, use of Entresto may be associated with an increased risk of hyperkalemia. In PARADIGM-HF, hyperkalemia resulted in treatment discontinuation in 0.26% of Entresto treated patients compared to 0.35% of enalapril treated patients. Medications known to raise potassium levels (e.g. potassium-sparing diuretics, potassium supplements) should be used with caution when co-administered with Entresto. If clinically significant hyperkalemia occurs, measures such as reducing dietary potassium, or adjusting the dose of concomitant medications should be considered. Dosage reduction or interruption of Entresto may be required. Monitoring of serum potassium is recommended especially in patients with risk factors such as severe renal impairment, diabetes mellitus, hypoaldosteronism or receiving a high potassium diet (see section 4 Dosage regimen and administration).

## **Angioedema**

Angioedema has been reported in patients treated with Entresto. If angioedema occurs, Entresto should be immediately discontinued and appropriate therapy and monitoring should be provided until complete and sustained resolution of signs and symptoms has occurred. Entresto must not be re-administered. In cases of confirmed angioedema where swelling has been

confined to the face and lips, the condition has generally resolved without treatment, although antihistamines have been useful in relieving symptoms.

Angioedema associated with laryngeal edema may be fatal. Where there is involvement of the tongue, glottis or larynx, likely to cause airway obstruction, appropriate therapy, e.g., subcutaneous epinephrine/adrenaline solution 1:1000 (0.3 mL to 0.5 mL) and/or measures necessary to ensure a patent airway, should be promptly administered.

Patients with a prior history of angioedema were not studied. As they may be at higher risk for angioedema, caution is recommended if Entresto is used in these patients. Entresto must not be used in patients with a known history of angioedema related to previous ACE inhibitor or ARB therapy or in patients with a history of hereditary or idiopathic angioedema (see section 5 Contraindications).

Black patients may have increased susceptibility to develop angioedema.

### **Patients with renal artery stenosis**

Similar to other drugs that affect the renin-angiotensin-aldosterone system, Entresto may increase blood urea and serum creatinine levels in patients with bilateral or unilateral renal artery stenosis. Caution is required in patients with renal artery stenosis and monitoring of renal function is recommended.

## **7 Adverse drug reactions**

### **Heart Failure**

#### **Summary of the safety profile**

The safety of Entresto in patients with chronic heart failure was evaluated in the pivotal phase 3 study PARADIGM-HF, which compared patients treated twice daily with Entresto 200 mg (n= 4,203) or enalapril 10 mg (n= 4,229). Patients randomized to Entresto received treatment for up to 4.3 years, with a median duration of exposure of 24 months; 3271 patients were treated for more than one year.

Discontinuation of therapy due to an AE in the double-blind period of the PARADIGM-HF trial occurred in 450 (10.71%) of Entresto treated patients and 516 (12.20%) of patients receiving enalapril. The events most commonly associated with dosage adjustment or treatment interruption were hypotension, hyperkalemia and renal impairment.

The overall incidence of adverse drug reactions (ADRs) of Entresto in heart failure patients was comparable to enalapril. The pattern of the ADRs is consistent with the pharmacology of Entresto and the patients underlying conditions.

The overall frequency of adverse reactions was not related to gender, age, or race.

Adverse drug reactions are ranked by System Organ Class and then by frequency with the most frequent first, using the following convention: very common ( $\geq 1/10$ ); common ( $\geq 1/100$  to  $< 1/10$ ); uncommon ( $\geq 1/1,000$  to  $< 1/100$ ); rare ( $\geq 1/10,000$  to  $< 1/1,000$ ); very rare ( $< 1/10,000$ ), including isolated reports. Within each frequency grouping, adverse reactions are ranked in order of decreasing seriousness.

**Table 1 Adverse Drug Reactions in the PARADIGM-HF, Safety Set**

Adverse drug reactions	Entresto 200mg twice daily (%)*	Enalapril 10 mg twice daily (%)*	Frequency category
<b>Metabolism and nutrition disorders</b>			
Hyperkalaemia	11.61	14.00	Very common
Hypokalaemia	3.31	2.53	Common
<b>Nervous system disorders</b>			
Syncope	2.24	2.70	Common
Dizziness	6.33	4.87	Common
Dizziness postural	0.57	0.28	Uncommon
Headache	2.45	2.51	Common
<b>Ear and labyrinth disorders</b>			
Vertigo	1.45	1.40	Common
<b>Vascular disorders</b>			
Hypotension	17.61	11.97	Very common
Orthostatic hypotension	1.52	0.80	Common
<b>Respiratory, thoracic and mediastinal disorders</b>			
Cough	8.78	12.60	Common
<b>Gastrointestinal disorders</b>			
Diarrhoea	4.62	4.47	Common
Nausea	2.09	2.36	Common
<b>Skin and subcutaneous tissue disorders</b>			
Angioedema	0.45	0.24	Uncommon
<b>Renal and urinary disorders</b>			
Renal impairment	10.14	11.52	Very Common
Renal failure (renal failure, acute renal failure)	4.76	5.30	Common
<b>General disorders and administration site conditions</b>			
Fatigue	2.97	3.05	Common
Asthenia	2.09	1.84	Common

\* Safety analysis set

## Essential Hypertension

### Summary of the safety profile

The safety of Entresto in patients with essential hypertension was evaluated in clinical trials involving more than 7,000 hypertensive patients (over 3,500 treated with Entresto).

In a pooled group of short-term, double-blind, controlled studies, 3,272 patients were exposed to Entresto with median duration of 8 weeks, dizziness occurred at a higher frequency in patients treated with Entresto than in patients treated with olmesartan (see Table 2).

Adverse drug reactions are ranked by System Organ Class and then by frequency with the most frequent first, using the following convention: very common ( $\geq 1/10$ ); common ( $\geq 1/100$  to  $< 1/10$ ); uncommon ( $\geq 1/1,000$  to  $< 1/100$ ); rare ( $\geq 1/10,000$  to  $< 1/1,000$ ); very rare ( $< 1/10,000$ ),

including isolated reports. Within each frequency grouping, adverse reactions are ranked in order of decreasing seriousness.

**Table 2 Adverse Drug Reactions in the pooled hypertension clinical studies**

Adverse drug reactions	Entresto	Olmesartan monotherapy	Frequency category
	N= 3272 n (%)	N=1352 n (%)	
<b>Nervous system disorders</b>			
Dizziness	49 (1.5)	12 (0.9)	Common

**Adverse drug reactions from spontaneous reports and literature cases (frequency not known)**

The following adverse drug reactions have been derived from post-marketing experience with Entresto via spontaneous case reports and literature cases. Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency, which is therefore categorized as not known. Adverse drug reactions are listed according to system organ classes in MedDRA.

**Table 3 Adverse Drug Reactions from spontaneous reports and literature cases (frequency not known)**

<b>Immune system disorders</b> Hypersensitivity (including rash, pruritus, and anaphylaxis)
--

## 8 Interactions

### Anticipated interactions resulting in a contraindication

**ACE inhibitors:** The concomitant use of Entresto with ACE inhibitors is contraindicated, as the concomitant inhibition of neprilysin (NEP) and ACE inhibitor therapy may increase the risk of angioedema. Entresto must not be started until 36 hours after taking the last dose of ACE inhibitor therapy. ACE inhibitor therapy must not be started until 36 hours after the last dose of Entresto (see sections 5 Contraindications, and 4 Dosage regimen and administration).

**Aliskiren:** The concomitant use of Entresto with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (eGFR < 60ml/min/1.73 m<sup>2</sup>) (see section 5 Contraindications).

The combination of Entresto with direct renin inhibitors such as aliskiren is not recommended. Combination of Entresto with aliskiren is potentially associated with a higher frequency of adverse events such as hypotension, hyperkalemia and decreased renal function (including acute renal failure) (see sections 5 Contraindications and 6 Warnings and precautions).



## Anticipated interactions resulting in concomitant use not being recommended

Entresto should not be co-administered with an ARB due to the angiotensin II receptor blocking activity of Entresto (see section 6 Warnings and precautions).

## Observed interactions to be considered

**Statins:** *In vitro* data indicates that sacubitril inhibits OATP1B1 and OATP1B3 transporters. Entresto may therefore increase the systemic exposure of OATP1B1 and OATP1B3 substrates such as statins. Co-administration of Entresto increased the C<sub>max</sub> of atorvastatin and its metabolites by up to 2-fold and AUC by up to 1.3-fold. Caution should be exercised upon co-administration of Entresto with statins. No clinically relevant drug-drug interaction was observed when simvastatin and Entresto were co-administered.

**Sildenafil:** Addition of a 50mg single dose of sildenafil to Entresto at steady state (400mg Entresto once daily for 5 days) in patients with hypertension was associated with additional blood pressure (BP) reduction (-5/4 mmHg, systolic/diastolic 24h-ambulatory BP) compared to administration of Entresto alone. Therefore, caution should be exercised when sildenafil or another PDE-5 inhibitor is initiated in patients treated with Entresto.

## Anticipated interactions to be considered

**Potassium:** Concomitant use of potassium-sparing diuretics (e.g. triamterene, amiloride), mineralocorticoid antagonists (e.g. spironolactone, eplerenone), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium, and to increases in serum creatinine. Monitoring of serum potassium is recommended if Entresto is co-administered with these agents (see section 6 Warnings and precautions).

**Non-Steroidal Anti-Inflammatory Agents (NSAIDs)** including selective cyclooxygenase-2 inhibitors (COX-2 Inhibitors): In elderly patients, volume-depleted patients (including those on diuretic therapy), or patients with compromised renal function, concomitant use of Entresto and NSAIDs may lead to an increased risk of worsening of renal function. Therefore, monitoring of renal function is recommended when initiating or modifying the treatment in patients on Entresto who are taking NSAIDs concomitantly.

**Lithium:** The potential for a drug interaction between Entresto and lithium has not been investigated. Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with ACE inhibitors or angiotensin II receptor antagonists. Therefore, careful monitoring of serum lithium levels is recommended during concomitant use with Entresto. If a diuretic is also used, the risk of lithium toxicity may be increased further.

**Transporters:** The active metabolite of sacubitril (sacubitrilat), and valsartan are OATP1B1, OATP1B3 and OAT3 substrates; valsartan is also a MRP2 substrate. Therefore, co-administration of Entresto with inhibitors of OATP1B1, OATP1B3, OAT3 (e.g. rifampin, cyclosporine) or MRP2 (e.g. ritonavir) may increase the systemic exposure to sacubitrilat or valsartan, respectively. Exercise appropriate care when initiating or ending concomitant treatment with such drugs.

**Furosemide:** Co-administration of Entresto and furosemide had no effect on the pharmacokinetics of Entresto but reduced C<sub>max</sub>, and AUC of furosemide by 50% and 28%, respectively. While there was no relevant change in urine volume, the urinary excretion of sodium was reduced within 4 hours and 24 hours after co-administration. The average daily dose of furosemide was unchanged from baseline until the end of the PARADIGM-HF study in patients treated with Entresto.

**Metformin:** Co-administration of Entresto with metformin reduced both C<sub>max</sub> and AUC of metformin by 23%. The clinical relevance of these findings is unknown. Therefore, when initiating therapy with Entresto in patients receiving metformin, the clinical status of the patient should be evaluated.

### **No significant interactions**

No clinically meaningful drug-drug interaction was observed upon co-administration of Entresto and digoxin, warfarin, hydrochlorothiazide, amlodipine, omeprazole, carvedilol, intravenous nitroglycerin or a combination of levonorgestrel/ethinyl estradiol.

*CYP 450 Interactions:* In vitro metabolism studies indicate that the potential for CYP 450 - based drug interactions is low since there is limited metabolism of Entresto via the CYP450 enzymes. Entresto does not induce or inhibit CYP450 enzymes.

## **9 Pregnancy, lactation, females and males of reproductive potential**

### **9.1 Pregnancy**

#### **Risk Summary**

As for other drugs that also act directly on the RAAS, Entresto must not be used during pregnancy (see section 5 Contraindications). Entresto exerts its effects via angiotensin II antagonism. As a result, a risk to the fetus cannot be excluded. There have been reports of injury to the developing fetus (e.g. spontaneous abortion, oligohydramnios and newborn renal dysfunction), when pregnant women have taken valsartan. Patients should be advised to discontinue Entresto as soon as pregnancies occur and to inform their physicians.

#### **Animal Data**

Entresto treatment during organogenesis resulted in increased embryo-fetal lethality in rats at doses  $\geq 100$  mg/kg/day [ $\leq 0.72$ -fold the MRHD on the basis of AUC] and rabbits at doses  $\geq 10$  mg/kg/day [2-fold and 0.03-fold the MRHD on the basis of valsartan and sacubitrilat AUC, respectively]. Entresto is teratogenic based on a low incidence of fetal hydrocephaly, associated with maternally toxic doses, which was observed in rabbits at a Entresto dose of  $\geq 10$  mg/kg/day. The adverse embryo-fetal effects of Entresto are attributed to the angiotensin receptor antagonist activity.

Pre- and postnatal development studies in rats conducted with sacubitril at doses up to 750 mg/kg/day [2.2-fold the MRHD on the basis of AUC] and valsartan at doses up to 600 mg/kg/day [0.86-fold the MRHD on the basis of AUC] indicate that treatment with Entresto during organogenesis, gestation and lactation may affect pup development and survival.

## **9.2 Lactation**

### **Risk Summary**

It is not known whether the components of Entresto are transferred into human milk. The components of Entresto, sacubitril and valsartan, were transferred into the milk of lactating rats. Because of the potential risk for adverse drug reactions in breastfed newborns/infants, Entresto is not recommended during breastfeeding. A decision should be made whether to abstain from breast-feeding or to discontinue Entresto while breast-feeding, taking into account the importance of Entresto to the mother.

## **9.3 Females and males of reproductive potential**

Female patients of child-bearing potential should be advised about the consequences of exposure to Entresto during pregnancy and to use contraception during treatment with Entresto and for 1 week after their last dose.

### **Infertility**

There are no available data on the effect of Entresto on human fertility. Entresto did not show any effects on fertility or early embryonic development in rats up to a dose of 150 mg/kg/day ( $\leq 1.0$  fold and  $\leq 0.18$  fold the MRHD on the basis of valsartan and sacubitrilat AUC, respectively).

## **10 Overdosage**

Limited data are available with regards to overdosage in human subjects with Entresto. In healthy volunteers, a single dose of Entresto 1200 mg, and 900 mg multiple doses (14 days) have been studied and were well tolerated.

Hypotension is the most likely symptom of overdosage due to the blood pressure lowering effects of Entresto. Symptomatic treatment should be provided.

Entresto is unlikely to be removed by hemodialysis due to high protein binding.

## **11 Clinical pharmacology**

### **Pharmacotherapeutic group, ATC**

Pharmacotherapeutic group: Agents acting on the renin-angiotensin system; angiotensin II antagonists, other combinations, ATC code: C09DX04.

### **Mechanism of action (MOA)**

Entresto exhibits the novel mechanism of action of an angiotensin receptor neprilysin inhibitor (ARNI) by simultaneously inhibiting neprilysin (neutral endopeptidase; NEP) via sacubitrilat, the active metabolite of the prodrug sacubitril, and by blocking the angiotensin II type-1 (AT1) receptor via valsartan. The complementary cardiovascular benefits and renal effects of Entresto in heart failure patients are attributed to the enhancement of peptides that are degraded by neprilysin, such as natriuretic peptides (NP), by sacubitrilat and the simultaneous inhibition of

the deleterious effects of angiotensin II by valsartan. NPs exert their effects by activating membrane-bound guanylyl cyclase-coupled receptors, resulting in increased concentrations of the second messenger cyclic guanosine monophosphate (cGMP), thereby promoting vasodilation, natriuresis and diuresis, increased glomerular filtration rate and renal blood flow, inhibition of renin and aldosterone release, reduction of sympathetic activity, and anti-hypertrophic and anti-fibrotic effects. Sustained activation of the renin-angiotensin-aldosterone system results in vasoconstriction, renal sodium and fluid retention, activation of cellular growth and proliferation, and subsequent maladaptive cardiovascular remodeling. Valsartan inhibits detrimental cardiovascular and renal effects of angiotensin II by selectively blocking the AT1 receptor, and also inhibits angiotensin II-dependent aldosterone release.

## **Pharmacodynamics (PD)**

The pharmacodynamic effects of Entresto were evaluated after single and multiple dose administrations in healthy subjects and in patients with heart failure, and are consistent with simultaneous neprilysin inhibition and RAAS blockade. In a 7-day valsartan-controlled study in patients with reduced ejection fraction (HFrEF), administration of Entresto resulted in a significant non-sustained increase in natriuresis, increased urine cGMP, and decreased plasma MR-proANP and NT-proBNP compared to valsartan. In a 21-day study in HFrEF patients, Entresto significantly increased urine ANP and cGMP and plasma cGMP, and decreased plasma NT-proBNP, aldosterone and endothelin-1 compared to baseline. Entresto also blocked the AT1-receptor as evidenced by increased plasma renin activity and plasma renin concentrations. In PARADIGM-HF, Entresto decreased plasma NT-proBNP and increased plasma BNP and urine cGMP compared with enalapril. While BNP is a neprilysin substrate, NT-proBNP is not. Therefore, NT-proBNP (but not BNP) is a suitable biomarker for monitoring of heart failure patients treated with Entresto.

In a thorough QTc clinical study in healthy male subjects, single doses of 400 mg and 1,200 mg Entresto had no effect on cardiac repolarization.

Neprilysin is one of multiple enzymes involved in the clearance of amyloid-beta (A-beta) from the brain and cerebrospinal fluid (CSF). Administration of Entresto 400 mg once daily for 2 weeks to healthy subjects was associated with an increase in CSF A-beta 1-38 compared to placebo; there were no changes in concentrations of CSF A-beta 1-40 and 1-42. The clinical relevance of this finding is unknown (see section 13 Non-clinical safety data).

## **Pharmacokinetics (PK)**

### **Absorption**

Following oral administration, Entresto dissociates into sacubitril, which is further metabolized to sacubitrilat, and valsartan, which reach peak plasma concentrations in 0.5 hours, 2 hours, and 1.5 hours, respectively. The oral absolute bioavailability of sacubitril and valsartan is estimated to be  $\geq 60\%$  and 23%, respectively. The valsartan in Entresto is more bioavailable than the valsartan in other marketed tablet formulations.

Following twice daily dosing of Entresto, steady state levels of sacubitril, sacubitrilat, and valsartan are reached in 3 days. At steady state, sacubitril and valsartan do not accumulate significantly, while sacubitrilat accumulates by 1.6-fold. Following once daily dosing of

Entresto, steady state levels of sacubitril, sacubitrilat and valsartan are achieved in 5 days with no accumulation in sacubitril and valsartan and 1.2-fold accumulation in sacubitrilat.

Entresto administration with food has no clinically significant impact on the systemic exposures of sacubitril, sacubitrilat and valsartan. Although there is a decrease in exposure to valsartan when Entresto is administered with food, this decrease is not accompanied by a clinically significant reduction in the therapeutic effect. Entresto can therefore be administered with or without food.

### **Distribution**

Entresto is highly bound to plasma proteins (94% - 97%). Based on the comparison of plasma and CSF exposures, sacubitrilat does cross the blood brain barrier to a limited extent (0.28%). The average apparent volumes of distribution of valsartan and sacubitril are 75 to and 103L respectively.

### **Biotransformation/metabolism**

Sacubitril is readily converted to sacubitrilat by esterases; sacubitrilat is not further metabolized to a significant extent. Valsartan is minimally metabolized, as only about 20% of the dose is recovered as metabolites. A hydroxyl metabolite has been identified in plasma at low concentrations (<10%). Since CYP450 enzyme mediated metabolism of sacubitril and valsartan is minimal, co-administration with drugs that impact CYP450 enzymes is not expected to impact the pharmacokinetics.

### **Elimination**

Following oral administration, 52 to 68% of sacubitril (primarily as sacubitrilat) and ~13% of valsartan and its metabolites are excreted in urine; 37 to 48% of sacubitril (primarily as sacubitrilat), and 86% of valsartan and its metabolites are excreted in feces.

Sacubitril, sacubitrilat, and valsartan are eliminated from plasma with a mean elimination half-life (T<sub>1/2</sub>) of approximately 1.43 hours, 11.48 hours, and 9.90 hours, respectively.

### **Linearity/non-linearity**

The pharmacokinetics of sacubitril, sacubitrilat, and valsartan are linear in the dose range tested (50 to 400 mg of Entresto).

### **Special populations**

#### **Pediatric patients (aged below 18 years)**

Entresto has not been studied in pediatric patients.

#### **Geriatric patients (65 years of age and above)**

The exposures of sacubitrilat and valsartan are increased in elderly subjects by 42% and 30%, respectively, compared to younger subjects. However, this is not associated with clinically relevant effects and therefore no dosage adjustment is necessary.

## **Gender**

The pharmacokinetics of Entresto (sacubitril, sacubitrilat and valsartan) are similar between male and female subjects.

## **Race/Ethnicity groups**

The pharmacokinetics of Entresto (sacubitril, sacubitrilat and valsartan) are comparable across different race and ethnic groups (Caucasians, Blacks, Asians, Japanese and others).

## **Renal impairment**

A correlation was observed between renal function and systemic exposure to sacubitrilat, but not to valsartan. In patients with mild ( $60 \text{ mL/min/1.73 m}^2 \leq \text{eGFR} < 90 \text{ mL/min/1.73 m}^2$ ) to moderate ( $30 \text{ mL/min/1.73 m}^2 \leq \text{eGFR} < 60 \text{ mL/min/1.73 m}^2$ ) renal impairment, the AUC for sacubitrilat was up to 2-fold higher. No dosage adjustment is required in patients with mild or moderate renal impairment. A 2.7-fold higher AUC for sacubitrilat was observed in patients with severe renal impairment ( $\text{eGFR} < 30 \text{ mL/min/1.73 m}^2$ ). A starting dose of 50 mg twice daily is recommended in heart failure patients with severe renal impairment. Caution is recommended when administering Entresto to these patients due to limited data. Safety and efficacy of Entresto in patients with essential hypertension and with severe renal impairment have not been established.

No studies have been performed in patients undergoing dialysis. However, sacubitrilat and valsartan are highly bound to plasma protein and, therefore, unlikely to be effectively removed by dialysis.

## **Hepatic impairment**

In patients with mild to moderate hepatic impairment, the exposures of sacubitril increased by 1.5- and 3.4- fold, sacubitrilat increased by 1.5- and 1.9-fold, and valsartan increased by 1.2-fold and 2.1-fold, respectively, compared to matching healthy subjects. No dosage adjustment is recommended when administering Entresto to patients with mild hepatic impairment (Child-Pugh A classification) including patients with biliary obstructive disorders. In patients with moderate hepatic impairment (Child-Pugh B classification), a starting dose of 50 mg twice daily is recommended in patients with heart failure and 100 mg once daily in hypertensive patients. Entresto has not been studied in patients with severe hepatic impairment. Therefore, its use is not recommended in patients with severe hepatic impairment.

# **12 Clinical studies**

## **Heart Failure**

### **PARADIGM-HF**

PARADIGM-HF was a multinational, randomized, double-blind study of 8,442 patients comparing Entresto to enalapril, both given to adult patients with chronic heart failure, NYHA class II – IV, and systolic dysfunction (left ventricular ejection fraction  $\leq 40\%$ ), in addition to other heart failure therapy. The primary endpoint was the composite of cardiovascular (CV) death or hospitalization for heart failure (HF).

Prior to study participation, patients were well treated with standard of care therapy which included ACE inhibitors/ARBs (>99%), beta-blockers (94%), mineralocorticoid antagonists (58%), and diuretics (83%). The median follow-up duration was 27 months and patients were treated for up to 4.3 years.

Patients were required to discontinue their existing ACE inhibitor or ARB therapy and entered a sequential single-blind run-in period during which patients received treatment with enalapril 10 mg twice daily, followed by treatment with Entresto 100 mg twice daily, increasing to 200 mg twice daily. Patients were then randomized to the double-blind period of the study to receive either Entresto 200 mg or enalapril 10 mg twice daily [Entresto (n= 4,209); enalapril (n= 4,233)].

The mean age of the population studied was 64 years of age and 19% were 75 years or older. At randomization, 70% of patients were NYHA Class II, 24% were NYHA Class III, and 0.7% were NYHA Class IV.

In the Entresto group, 76% of patients remained on the target dose of 200 mg twice daily at the end of the study (mean daily dose of 375 mg). In the enalapril group, 75% of patients remained on the target dose of 10 mg twice daily at the end of the study (mean daily dose of 18.9 mg).

Entresto demonstrated clinically relevant and statistically significant superiority to enalapril, reducing the risk of cardiovascular death or heart failure hospitalizations by 20% (hazard ratio (HR): 0.80, 95% CI [0.73; 0.87], 1-sided p =0.0000002) versus enalapril. This effect was observed early and was sustained throughout the duration of the trial. The absolute risk reduction was 4.69%. A statistically significant reduction for CV death and first HF hospitalization was observed (CV death, RRR 20%, HR 0.80; 95% CI [0.71, 0.89], 1-sided p= 0.00004; and hospitalization for heart failure RRR 21%; HR 0.79; 95% CI 0.71, 0.89], 1-sided p= 0.00004); see Table 3 and Figure 1. Sudden death accounted for 45% of cardiovascular deaths and was reduced by 20% in Entresto treated patients compared to enalapril treated patients (HR 0.80, p= 0.0082). Pump failure accounted for 26% of cardiovascular deaths and was reduced by 21% in Entresto treated patients compared to enalapril treated patients (HR 0.79, p = 0.0338).

This risk reduction was consistently observed across subgroups including: age, gender, race, geography, NYHA class, ejection fraction, renal function, history of diabetes or hypertension, prior heart failure therapy, and atrial fibrillation.

Entresto also significantly reduced all-cause mortality by 16% compared with enalapril (RRR 16%, HR 0.84; 95% CI [0.76 to 0.93], 1-sided p=0.0005) (Table 3). The absolute risk reduction was 2.84%.

**Table 4 Treatment effect for the primary composite endpoint, its components and all-cause mortality**

	<b>Entresto</b> N = 4187 <sup>#</sup> n (%)	<b>Enalapril</b> N = 4212 <sup>#</sup> n (%)	<b>Hazard Ratio</b> <b>(95% CI)</b>	<b>Relative</b> <b>Risk</b> <b>Reduction</b>	<b>p-value</b> <b>***</b>
Primary Composite Endpoint of CV Death and Heart Failure Hospitalizations*	914 (21.83)	1117 (26.52)	0.80 (0.73, 0.87)	20%	0.0000002
<b>Individual Components of the primary composite endpoint</b>					

CV Death **	558 (13.33)	693 (16.45)	0.80 (0.71, 0.89)	20%	0.00004
First Heart Failure Hospitalization	537 (12.83)	658 (15.62)	0.79 (0.71, 0.89)	21%	0.00004
<b>Secondary Endpoint</b>					
All-cause mortality	711 (16.98)	835 (19.82)	0.84 (0.76, 0.93)	16%	0.0005

\*The primary endpoint was defined as the time to first event.


\*\* CV death includes all patients who died up to the cut-off date irrespective of previous hospitalization.

\*\*\* One-sided p-value.

‡ Full analysis set

The Kaplan-Meier presented in the figure below (left) shows time to first occurrence of the primary composite endpoint of CV death or heart failure hospitalization. Entresto treatment effect was evident early and sustained for the duration of the study. The Kaplan-Meier figure presented below (right) shows the time to CV death endpoint.

**Figure 1 Kaplan-Meier curves for the primary composite endpoint and the CV death component**



Overall, there were fewer all cause hospital admissions in patients treated with Entresto compared to enalapril, including a 12% relative risk reduction for the first hospitalization (HR 0.88 [95% CI: 0.82, 0.94], P<0.001), and a 16% relative rate reduction for total number of hospitalizations (RR 0.84 [95% CI: 0.78, 0.91], P<0.001).

## TITRATION

TITRATION was a 12 week safety and tolerability study in 538 patients with chronic heart failure (NYHA class II – IV) and systolic dysfunction (left ventricular ejection fraction ≤ 35%) naïve to ACE inhibitor or ARB therapy or on varying doses of ACE inhibitors or ARBs prior to study entry. Patients initiated Entresto 50 mg twice daily, were uptitrated to 100 mg twice daily and then to the target dose of 200 mg twice daily with either a 3-week or 6-week regimen.

Overall, 76% of patients achieved and maintained the target dose of Entresto 200 mg twice daily without any dose interruption or down-titration over 12-weeks. More patients who were naïve to previous ACE inhibitor or ARB therapy or on low dose therapy (equivalent to < 10 mg



of enalapril/ day) were able to achieve and maintain Entresto 200 mg twice daily dose when uptitrated over 6 weeks versus 3 weeks.

### **Essential Hypertension**

The antihypertensive effect of Entresto was evaluated in two randomized, double-blind, active-controlled, 8-week studies evaluating the efficacy and safety of Entresto in comparison to olmesartan (CLCZ696A2315 and CLCZ696A1306) in more than 2,500 adult patients of which more than 1,700 patients received Entresto. Both studies demonstrated non-inferiority as well as superiority of the mean sitting systolic blood pressure (msSBP) lowering effect of both Entresto 200 mg once daily (2.3 and 5.0 mmHg in each study, respectively) and Entresto 400 mg once daily (3.5 and 7.0 mmHg) compared to olmesartan 20 mg once daily. Consistent results were observed in mean diastolic BP.

Additionally, persistency of blood pressure lowering effect was demonstrated in a 52-week, safety, tolerability and efficacy, open-label, extension study (CLCZ696A2219E1) in which 341 patients were receiving Entresto as a monotherapy or in combination with amlodipine and hydrochlorothiazide.

## **13 Non-clinical safety data**

Non-clinical safety studies conducted with Entresto included assessment of safety pharmacology, repeated dose toxicity genotoxicity carcinogenicity and reproductive and development toxicity Entresto had no adverse effects on vital organ systems. Most findings seen in repeated toxicity studies were reversible and attributable to the pharmacology of AT<sub>1</sub> receptor blockade.

### **Carcinogenicity, mutagenesis and genetic toxicity**

Carcinogenicity studies conducted in mice and rats with sacubitril and valsartan did not identify any carcinogenic potential for Entresto. The doses of sacubitril studied (high dose of 1,200 and 400 mg/kg/day in mice and rats, respectively) were about 29 and 19 times, respectively, the maximum recommended human dose (MRHD) on a mg/m<sup>2</sup> basis. The doses of valsartan studied (high dose of 160 and 200 mg/kg/day in mice and rats, respectively) were about 4 and 10 times, respectively, the maximum recommended human dose on a mg/m<sup>2</sup> basis.

Mutagenicity and clastogenicity studies conducted with Entresto, sacubitril, and valsartan did not reveal any effects at either the gene or chromosome level.

### **Fertility, reproduction and development**

See section 9 Pregnancy, lactation, females and males of reproductive potential.

### **Other preclinical findings**

The effects of Entresto on amyloid-beta concentrations in cerebrospinal fluid (CSF) and brain tissue were assessed in young (2 to 4 years old) cynomolgus monkeys treated with Entresto (50 mg/kg/day) for 2 weeks. In this study, Entresto had a pharmacodynamic effect on CSF A-beta clearance in cynomolgus monkeys, increasing CSF A-beta 1-40, 1-42, and 1-38 levels; there

was no corresponding increase in A-beta levels in the brain. Increases in CSF A-beta 1-40 and 1-42 were not observed in a 2 week healthy volunteer study in humans (see section 11 Clinical pharmacology). Additionally, in a toxicology study in cynomolgus monkeys treated with Entresto at 300 mg/kg/day for 39-weeks, there was no amyloid-beta accumulation in the brain.

## **14 Pharmaceutical information**

### **Incompatibilities**

Not applicable.

### **Special precautions for storage**

Do not store above 30°C. Store in the original package to protect from moisture Entresto should not be used after the date marked “EXP” on the pack.

Entresto must be kept out of the reach and sight of children.

### **Instructions for use and handling**

Not applicable.

### **Manufacturer:**

See folding box.

### **Presentation:**

Entresto 50mg: 2 x 14s

Entresto 100mg: 4 x 14s

Entresto 200mg: 8 x 7s

Not all presentations may be available locally.

® = registered trademark

**Novartis Pharma AG, Basel, Switzerland**